Shenzhen - Delayed Quote CNY

Shanghai RAAS Blood Products Co., Ltd. (002252.SZ)

Compare
7.22
0.00
(0.00%)
At close: December 20 at 3:04:39 PM GMT+8
Loading Chart for 002252.SZ
DELL
  • Previous Close 7.22
  • Open 7.24
  • Bid 7.22 x --
  • Ask 7.23 x --
  • Day's Range 7.19 - 7.27
  • 52 Week Range 5.93 - 8.68
  • Volume 24,676,372
  • Avg. Volume 49,106,394
  • Market Cap (intraday) 47.926B
  • Beta (5Y Monthly) 0.52
  • PE Ratio (TTM) 25.79
  • EPS (TTM) 0.28
  • Earnings Date --
  • Forward Dividend & Yield 0.07 (0.93%)
  • Ex-Dividend Date Sep 30, 2024
  • 1y Target Est 6.40

Shanghai RAAS Blood Products Co., Ltd. engages in the manufacture and sale of blood products in China. It offers human serum albumin, human intravenous immunoglobulin, human coagulation factor VIII, human prothrombin complex, human fibrinogen, human thrombin and human fibrin adhesive, human immunoglobulin, hepatitis B immunoglobulin, tetanus immunoglobulin, and rabies immunoglobulin products. Shanghai RAAS Blood Products Co., Ltd. was founded in 1988 and is based in Shanghai, China.

www.raas-corp.com

3,254

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 002252.SZ

View More

Performance Overview: 002252.SZ

Trailing total returns as of 12/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

002252.SZ
8.91%
SSE Composite Index
14.29%

1-Year Return

002252.SZ
9.02%
SSE Composite Index
17.29%

3-Year Return

002252.SZ
11.41%
SSE Composite Index
6.02%

5-Year Return

002252.SZ
0.06%
SSE Composite Index
13.06%

Compare To: 002252.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 002252.SZ

View More

Valuation Measures

As of 12/27/2024
  • Market Cap

    47.93B

  • Enterprise Value

    44.22B

  • Trailing P/E

    25.69

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.65

  • Price/Book (mrq)

    1.54

  • Enterprise Value/Revenue

    5.30

  • Enterprise Value/EBITDA

    19.56

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    21.93%

  • Return on Assets (ttm)

    4.32%

  • Return on Equity (ttm)

    6.00%

  • Revenue (ttm)

    8.34B

  • Net Income Avi to Common (ttm)

    1.83B

  • Diluted EPS (ttm)

    0.28

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.71B

  • Total Debt/Equity (mrq)

    0.00%

  • Levered Free Cash Flow (ttm)

    103.73M

Research Analysis: 002252.SZ

View More

People Also Watch